Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD Cash & Equivalents

Cash & Equivalents at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
HRO
HarrowHROW
$94.64M+41.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$176.35M+51.7%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$666.7M+90.7%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$155.66M-43.4%
Vera Therapeutics logo
Vera TherapeuticsVERA
$114.35M+108%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's cash & equivalents?
Kodiak Sciences Inc (KOD) reported cash & equivalents of $169.53M in Q1 2026.
How has Kodiak Sciences Inc's cash & equivalents changed year-over-year?
Kodiak Sciences Inc's cash & equivalents increased by 22.1% year-over-year, from $138.85M to $169.53M.
What is the long-term trend for Kodiak Sciences Inc's cash & equivalents?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's cash & equivalents has grown at a -26.0% compound annual growth rate (CAGR), from $944.4M to $209.86M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.